<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="anti-cancer effects of the nucleoside analogue 5-fluorouracil. Here, we combined" exact="omeprazole" post="with the antiviral nucleoside analogues ribavirin and acyclovir. Omeprazole"/>
 <result pre="5-fluorouracil. Here, we combined omeprazole with the antiviral nucleoside analogues" exact="ribavirin" post="and acyclovir. Omeprazole did not affect the antiviral effects"/>
 <result pre="and acyclovir. Omeprazole did not affect the antiviral effects of" exact="ribavirin" post="in non-toxic concentrations up to 80 μg/mL but increased"/>
 <result pre="reduced HSV-1-induced CPE formation by 50% (IC50). In HSV-2-infected cells," exact="omeprazole" post="80 μg/mL reduced the acyclovir IC50 by 7.3- (Vero"/>
 <result pre="7.3- (Vero cells) and 12.9-fold (HaCaT cells). In HaCaT cells," exact="omeprazole" post="80 μg/mL reduced the HSV-1 titer in the presence"/>
 <result pre="from severe complications. HSV HSV-1 HSV-2 antiviral therapy antiviral drugs" exact="ribavirin" post="proton pump inhibitors fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
 <result pre="Chemaly et al., 2019). Here, we investigated the effects of" exact="omeprazole" post="on the efficacy of the antiviral nucleoside analogues acyclovir"/>
 <result pre="influenza viruses and West Nile virus. The mechanisms by which" exact="ribavirin" post="interferes with virus replication are not clear and may"/>
 <result pre="al., 2018; Keppeke et al., 2019). Our findings show that" exact="omeprazole" post="(and other proton pump inhibitors) increase the antiviral activity"/>
 <result pre="Kärber, 1931). Drugs Acyclovir was received from GlaxoSmithKline (Munich, Germany)," exact="omeprazole" post="from AstraZeneca (Wedel, Germany), ribavirin from Valeant Pharmaceuticals Germany"/>
 <result pre="received from GlaxoSmithKline (Munich, Germany), omeprazole from AstraZeneca (Wedel, Germany)," exact="ribavirin" post="from Valeant Pharmaceuticals Germany GmbH (Eschborn, Germany), and pantoprazole,"/>
 <result pre="Results Effects of Omeprazole on Cell Viability The effects of" exact="omeprazole" post="on the viability of the investigated cell lines was"/>
 <result pre="Cells Omeprazole 80 μg/mL did not alter the effects of" exact="ribavirin" post="on CPE formation in WNV-infected Vero cells or H1N1-infected"/>
 <result pre="presence of antiviral nucleoside analogues and omeprazole. (A) Effects of" exact="omeprazole" post="(80 μg/mL) on the concentrations of antiviral nucleoside analogues"/>
 <result pre="values are presented in Supplementary Table S1. (B) Effects of" exact="omeprazole" post="and acyclovir on the expression of virus proteins in"/>
 <result pre="HSV-1- and HSV-2-infected Vero cells. HSV-1-infected cells were treated with" exact="omeprazole" post="80 μg/mL and/or acyclovir 0.31 μg/mL. HSV-2-infected cells were"/>
 <result pre="μg/mL and/or acyclovir 0.31 μg/mL. HSV-2-infected cells were treated with" exact="omeprazole" post="40 μg/mL and/or acyclovir 0.6 μg/mL. (C) HSV gB"/>
 <result pre="(C) HSV gB levels in HSV-1-infected Vero cells treated with" exact="omeprazole" post="80 μg/mL and/or acyclovir 0.31 μg/mL as determined by"/>
 <result pre="HSV-2-induced CPE formation (Supplementary Table S1). In the presence of" exact="omeprazole" post="80 μg/mL, however, acyclovir concentrations that reduced CPE formation"/>
 <result pre="HSV-2-infected Vero cells (Figure 1A and Supplementary Table S1). Further," exact="omeprazole" post="80 μg/mL reduced the acyclovir IC50s by 48-fold in"/>
 <result pre="numbers of virus-infected cells after treatment with a combination of" exact="omeprazole" post="and acyclovir compared to either single treatment (Figure 1B)."/>
 <result pre="treated with this combination (Figure 1C). Further experiments indicated that" exact="omeprazole" post="reduced acyclovir IC50s in HSV-1- and HSV-2-infected HaCaT cells"/>
 <result pre="2 and Supplementary Table S2). FIGURE 2 Concentration-dependent effects of" exact="omeprazole" post="on the acyclovir IC50 in HSV-1- or HSV-2-infected HaCaT"/>
 <result pre="combination. ∗P &amp;lt; 0.05 relative to nucleoside analogue alone. Although" exact="omeprazole" post="did not affect the HSV-1 and HSV-2 CPEs in"/>
 <result pre="of virus titers in Vero cells showed that 80 μg/mL" exact="omeprazole" post="inhibited the production of infectious HSV-1 particles and that"/>
 <result pre="of infectious HSV-1 particles and that 40 and 80 μg/mL" exact="omeprazole" post="inhibited the production of infectious HSV-2 particles. In agreement"/>
 <result pre="particles. In agreement with the findings from the CPE assays," exact="omeprazole" post="also strongly increased the anti-HSV-1 and anti-HSV-2 effects of"/>
 <result pre="omeprazole-induced increase of acyclovir activity was also seen at lower" exact="omeprazole" post="concentrations, which did not directly reduce virus titers (Figure"/>
 <result pre="virus titers (Figure 3 and Supplementary Table S3). The investigated" exact="omeprazole" post="and acyclovir concentrations did not affect cell viability, neither"/>
 <result pre="or 2 μg/mL (HSV-2) alone or in combination with varying" exact="omeprazole" post="(OME) concentrations (μg/mL) on HSV-1 and HSV-2 titres in"/>
 <result pre="acyclovir alone. Discussion Based on previous investigations that showed that" exact="omeprazole" post="increases the anti-cancer activity of the nucleoside analog 5-fluorouracil"/>
 <result pre="(Luciani et al., 2004), we here investigated the effects of" exact="omeprazole" post="on the antiviral effects of ribavirin and acyclovir. Omeprazole"/>
 <result pre="investigated the effects of omeprazole on the antiviral effects of" exact="ribavirin" post="and acyclovir. Omeprazole did not modify ribavirin-mediated effects in"/>
 <result pre="fashion in Vero and HaCaT cells. It remains unclear why" exact="omeprazole" post="increases the activity of acyclovir but not that of"/>
 <result pre="not that of ribavirin. Differences between the compounds acyclovir and" exact="ribavirin" post="including their mechanisms of action and/or differences between the"/>
 <result pre="viruses may be responsible for this. The mechanism by which" exact="omeprazole" post="enhances the activity of acyclovir seems to differ from"/>
 <result pre="of acyclovir seems to differ from the mechanism by which" exact="omeprazole" post="increases 5-fluorouracil efficacy, which was shown to be the"/>
 <result pre="lysosomal pH (Luciani et al., 2004). Lysosomotropic drugs such as" exact="chloroquine" post="and ammonium chloride are known to interfere with the"/>
 <result pre="Baines, 2011; Al-Bari, 2017; Salata et al., 2017). In agreement," exact="omeprazole" post="concentrations ≥40 μg/mL reduced HSV-1 and HSV-2 titers. However,"/>
 <result pre="μg/mL reduced HSV-1 and HSV-2 titers. However, the effects of" exact="omeprazole" post="on the anti-HSV activity of acyclovir were more pronounced"/>
 <result pre="were more pronounced than the direct antiviral effects and lower" exact="omeprazole" post="concentrations, which did not affect HSV-1 and HSV-2 replication,"/>
 <result pre="is not a direct consequence of antiviral activity exerted by" exact="omeprazole" post="and may be caused by a different mechanism. Moreover,"/>
 <result pre="omeprazole and may be caused by a different mechanism. Moreover," exact="omeprazole" post="pre-treatment was necessary to increase 5-fluorouracil activity (Luciani et"/>
 <result pre="necessary to increase 5-fluorouracil activity (Luciani et al., 2004), but" exact="omeprazole" post="and acyclovir exerted their combined activity when added at"/>
 <result pre="h post infection. This indicates that the mechanisms by which" exact="omeprazole" post="increases 5-fluorouracil and acyclovir activity differ and that omeprazole"/>
 <result pre="which omeprazole increases 5-fluorouracil and acyclovir activity differ and that" exact="omeprazole" post="increases the antiviral activity of acyclovir during the viral"/>
 <result pre="al., 2016; Nelson et al., 2017; Ghebre, 2018). In addition," exact="omeprazole" post="may inhibit DNA damage repair (Martelli et al., 1998),"/>
 <result pre="do not involve the modulation of the lysosomal pH. Since" exact="omeprazole" post="is a clinically well-established drug with a preferable safety"/>
 <result pre="not exert general immunosuppressive effects in the same way as" exact="hydrocortisone" post="but to more specifically increase acyclovir activity. In immunodeficiency"/>
 <result pre="be feasible in a severe acute disease setting. In conclusion," exact="omeprazole" post="and other proton pump inhibitors substantially enhance the antiviral"/>
 <result pre="References References Al-BariM. A. A. (2017). Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
 <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistance.Curr. Opin. Virol.810–15. 10.1016/j.coviro.2014.04.01124846716 BoukampP.PetrussevskaR. T.BreitkreutzD.HornungJ.MarkhamA.FusenigN. E. (1988). Normal"/>
 <result pre="of print]. KohC.LiangT. J. (2014). What is the future of" exact="ribavirin" post="therapy for hepatitis C?Antiviral Res.10434–39. 10.1016/j.antiviral.2014.01.00524468277 KoyamaA. H.UchidaT. (1984)."/>
 <result pre="Natl. Cancer Inst.961702–1713. 10.1093/jnci/djh30515547183 MartelliA.MattioliF.MeretoE.Brambilla CampartG.SiniD.BergamaschiG.et al. (1998). Evaluation of" exact="omeprazole" post="genotoxicity in a battery of in vitro and in"/>
 <result pre="Recent approval of Xerese in Canada: 5% acyclovir and 1%" exact="hydrocortisone" post="topical cream in the treatment of herpes labialis.Skin Therapy"/>
</results>
